In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV(1) reversibility

BACKGROUND: A post hoc analysis of two randomized, placebo–controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma. METHODS: Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1 s (FEV(1)) rever...

Descripción completa

Detalles Bibliográficos
Autores principales: Virchow, J. Christian, Hickey, Lisa, Du, Evelyn, Garin, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168990/
https://www.ncbi.nlm.nih.gov/pubmed/32328116
http://dx.doi.org/10.1186/s13223-020-00424-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168990/
https://www.ncbi.nlm.nih.gov/pubmed/32328116
http://dx.doi.org/10.1186/s13223-020-00424-2

Ejemplares similares